Analyst Price Target is GBX 0
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for EMIS Group in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 1,245.60.
Current Consensus is
The current consensus among 0 investment analysts is to n/a stock in EMIS Group. This rating has held steady since March 2020, when it changed from a Hold consensus rating.
EMIS Group plc, through its subsidiaries, provides connected healthcare software and systems for healthcare professionals in the United Kingdom. It operates in two segments, EMIS Health and EMIS Enterprise. The EMIS Health segment supplies integrated care technology to national health service markets, including primary, community, acute, and social care. The EMIS Enterprise segment focuses on B2B technology sector in the healthcare market, such as management of medicines, partner businesses, life sciences, and patient-facing services. The company offers clinical software to healthcare organizations under the EMIS brand; patient-centric medical and wellbeing information and digital front door services under the Patient brand name; and service management solutions to the community pharmacy market under the Pinnacle brand. It also operates Patient.info, an online health platform that provides personalized online patient-facing services and healthcare content; Patient Access, which enables people to book appointments; and ProScript and ProScript Connect that enable pharmacies to manage the dispensing process and handle tasks, such as labelling and endorsing, patient records, ordering, and stock control. In addition, the company provides non-clinical ICT solutions for healthcare professionals and other public and private sector organizations; and supplies ICT infrastructure and hosting services. The company was founded in 1987 and is headquartered in Leeds, the United Kingdom.